In vivo elongation of thin filaments results in heart failure.
Lei Mi-MiGerrie P FarmanRachel M MayfieldJoshua StromMiensheng ChuChristopher T PappasCarol C GregorioPublished in: PloS one (2020)
A novel cardiac-specific transgenic mouse model was generated to identify the physiological consequences of elongated thin filaments during post-natal development in the heart. Remarkably, increasing the expression levels in vivo of just one sarcomeric protein, Lmod2, results in ~10% longer thin filaments (up to 26% longer in some individual sarcomeres) that produce up to 50% less contractile force. Increasing the levels of Lmod2 in vivo (Lmod2-TG) also allows us to probe the contribution of Lmod2 in the progression of cardiac myopathy because Lmod2-TG mice present with a unique cardiomyopathy involving enlarged atrial and ventricular lumens, increased heart mass, disorganized myofibrils and eventually, heart failure. Turning off of Lmod2 transgene expression at postnatal day 3 successfully prevents thin filament elongation, as well as gross morphological and functional disease progression. We show here that Lmod2 has an essential role in regulating cardiac contractile force and function.
Keyphrases
- heart failure
- left ventricular
- mouse model
- atrial fibrillation
- poor prognosis
- hypertrophic cardiomyopathy
- skeletal muscle
- cardiac resynchronization therapy
- single molecule
- binding protein
- acute heart failure
- left atrial
- south africa
- preterm infants
- quantum dots
- type diabetes
- living cells
- catheter ablation
- amino acid
- insulin resistance
- smooth muscle
- fluorescent probe